ID   PC346Flu2
AC   CVCL_IP23
DR   cancercelllines; CVCL_IP23
DR   GEO; GSM539108
DR   GEO; GSM539109
DR   GEO; GSM539110
DR   GEO; GSM539111
DR   Wikidata; Q54938579
RX   PubMed=15900601;
RX   PubMed=20976069;
CC   Characteristics: Proliferation of this cell line is androgen-independent.
CC   Selected for resistance to: ChEBI; CHEBI:5132; Flutamide.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=15900601).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4883 ! PC-346C
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 12
//
RX   PubMed=15900601; DOI=10.1002/ijc.21201;
RA   Marques R.B., Erkens-Schulze S., de Ridder C.M.A., Hermans K.G.,
RA   Waltering K., Visakorpi T., Trapman J., Romijn J.C., van Weerden W.M.,
RA   Jenster G.;
RT   "Androgen receptor modifications in prostate cancer cells upon
RT   long-term androgen ablation and antiandrogen treatment.";
RL   Int. J. Cancer 117:221-229(2005).
//
RX   PubMed=20976069; DOI=10.1371/journal.pone.0013500; PMCID=PMC2957443;
RA   Marques R.B., Dits N.F., Erkens-Schulze S., van Weerden W.M.,
RA   Jenster G.;
RT   "Bypass mechanisms of the androgen receptor pathway in
RT   therapy-resistant prostate cancer cell models.";
RL   PLoS ONE 5:E13500-E13500(2010).
//